OMER Omeros Corporation Company Net Income

OMER (omeros.com) - company brandmark

Omeros Corporation (OMER) price action reflects a current level of 0.13. The business relies on developing drugs to combat immune pathologies, although dependence on regulatory verdicts creates certain risks. The firm's stability is bolstered by strategic collaboration with medical centers and scientists to identify targeted therapies for rare diseases and the mitigation of severe inflammation.

omeros.com (OMER): Net Profit from 07/04/2022 to 11/01/2026

Analytical breakdowns and data insights for company omeros.com (OMER)

- stock value and consensus price forecast:
Market Price Omeros|OMER - Price Target Chart
- market capitalization data:
Market Value Omeros Corporation|OMER - Total Company Value
- balance sheet equity data:
Accounting Value per Share Omeros|OMER - Book Capitalization|Market-to-Book Ratio omeros.com|OMER - Aggregate Company Assets
- debt and liquidity details:
All Debt to Shareholders' Equity Ratio Omeros Corporation|OMER - Long-Term Debt to Equity|Current Liabilities to Capital Omeros|OMER - Company Debts|Debts to Net Assets Omeros Corporation|OMER - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Omeros|Quick Liquidity Indicator omeros.com
- net income and valuation ratios data:
OMER - Company Net Income
Basic company analysis:OMER - Omeros Corp.
Manufactured products of Omeros Corporation

For Omeros Corporation (OMER), profit reflects the final efficiency of biopharmaceutical drug development. This metric measures the net remaining funds after deducting all operating expenses and debt service costs. An analysis of the company's marginal income allows for an assessment of the impact of credit rates on the issuer's financial stability. The volatility of this indicator correlates with the regulatory risks of approving key products. Profit stability confirms the brand's market viability despite investor caution.

Key competitors

Company Net Income Biogen Idec (BIIB)|Company Net Income Neurocrine Biosciences|Company Net Income regencellbioscience.com RGC|Company Net Income Axsome Therapeutics, Inc. (AXSM)|Net Income ACADIA Pharma ACAD|Net Profit XENE (Xenon Pharmaceuticals Inc)|Viking Therapeutics Corp (VKTX) - Company Net Income|SUPN - Company Net Income|Final Profit CPRX (catalystpharma.com)|Denali Therapeutics Inc. (DNLI) - Company Net Income|Company Net Income Harmony Biosciences Inc (HRMY)|Company Net Income Biohaven Pharmaceutical|Amylyx Corp (AMLX) - Net Financial Result|Net Income TRVI (Trevi Therapeutics)|PRAX (praxismedicines.com) - Final Profit|Net Profit AVXL (Anavex Life Sciences Corp.)|CBLL - Net Income|PRTA - Company Net Income|Company Net Income Alector, Inc.|Annexon, Inc. (ANNX) - Company Net Income|neurogene.com - Final Profit|Company Net Income AC Immune SA|Voyager Therapeutics Inc - Profit After Tax|Company Net Income Neumora Therapeutics Inc (NMRA)|SCLX - Company Net Income|Company Net Income Tevogen Bio Holdings TVGN|Final Profit ACOG|Cognition Therapeutics - Net Profit|IKT - Net Profit|SAVA (Cassava) - Net Income|ASRT: Profit After Payment of Taxes|COYA (Coya Therapeutics Inc) - Net Profit|VistaGen Therapeutics Inc (VTGN) - Net Financial Result|Company Net Income Ovid Therapeutics Inc. (OVID)|ABOS - Company Net Income|Company Net Income CervoMed Inc CRVO|ATHE: Company Profit|CLNN - Company Net Income|Company Net Income PepGen Inc.|Jupiter Neurosciences Inc (JUNS) - Company Net Income|Net Income Relmada Therapeutics Inc|ANVS (Annovis Bio Corp) - Net Profit|Company Net Income Grace Tx GRCE|Company Net Income Firefly Neuroscience, Inc (AIFF)|KLTO (anewmeds.com) - Final Profit|Company Net Income NeuroSense Therapeutics Ltd. NRSN|RVPH: Company Profit|MetaVia, Inc. - Net Profit|Company Net Income NeurAxis Inc|HSDT (heliusmedical.com) - Net Income|Passage Bio (PASG) - Net Profit|Company Net Income Neuphoria Therapeutics, Inc.|NERV: Final Profit|Company Net Income Athira (ATHA)|ADXN - Company Net Income|Company Net Income Alzamend Neuro ALZN|Cyclerion Therapeutics Inc. (CYCN) - Company Net Income|PTIX - Company Net Income|Pasithea Therapeutics (KTTA) - Net Income|CRGT: Net Profit|Company Net Income Avenue Therapeutics Inc (ATXI)|Company Net Income Brainstorm Cell|CARA: Final Profit|Company Net Income Chromocell Therapeutics Corp. (CHRO)|ELYM - Company Net Income|Company Net Income Intra-Cellular Therapies, Inc. ITCI|Net Financial Result Longboard (LBPH)|MRNS: Net Income|Final Profit NKGN (nkgenbiotech.com)|NRBO: Net Profit|Net Income Sage Therapeutics Inc.|Company Net Income Neurotrope|Company Net Income Trevena Inc TRVN|Company Net Income Vigil Neuroscience (VIGL)|WENA (Anew Medical Inc.) - Final Profit|Company Net Income Cerevel Therapeutics, Inc. CERE